dr. G.M. (Guus) Bol

Assistant Professor - medical

  • Department of Medical Oncology

Research Output (15)

Targeting mitochondrial translation by inhibiting DDX3:A novel radiosensitization strategy for cancer treatment

Heerma Van Voss M. R., Vesuna F., Bol G. M., Afzal J., Tantravedi Saritha, Bergman Y., Kammers Kai, Lehar M., Malek Reem, Ballew M., ter Hoeve N., Abou D., Thorek D., Berlinicke Cynthia, Yazdankhah M., Sinha D., le Couteur A., Abrahams R., Tran Phuoc T., Van Diest P. J., Raman V. 4 jan 2018, In: Oncogene. 37 , p. 63-74 12 p.

Nuclear DDX3 expression predicts poor outcome in colorectal and breast cancer

Heerma Van Voss Marise R., Vesuna Farhad, Bol Guus M., Meeldijk Jan, Raman Ana, Offerhaus G. Johan, Buerger Horst, Patel Arvind H., Van Der Wall Elsken, Van Diest Paul J., Raman Venu 17 jul 2017, In: OncoTargets and Therapy. 10 , p. 3501-3513 13 p.

Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer

Heerma van Voss Marise R., Brilliant Justin D., Vesuna Farhad, Bol Guus M., van der Wall Elsken, van Diest Paul J., Raman Venu 1 mrt 2017, In: Medical Oncology. 34

RK-33 radiosensitizes prostate cancer cells by blocking the RNA helicase DDX3

Xie Min, Vesuna Farhad, Tantravedi Saritha, Bol Guus M., Heerma van Voss Marise R, Nugent Katriana, Malek Reem, Gabrielson Kathleen, Van Diest Paul J., Tran Phuoc T., Raman Venu 1 nov 2016, In: Cancer Research. 76 , p. 6340-6350 11 p.

PLGA nanoparticle formulation of RK-33 an RNA helicase inhibitor against DDX3

Bol Guus Martinus, Khan Raheela, Heerma van Voss Marise Rosa, Tantravedi Saritha, Korz Dorian, Kato Yoshinori, Raman Venu okt 2016, In: Cancer Chemotherapy and Pharmacology. 76 , p. 821-827 7 p.

FOLFOX chemotherapy as a cause of ventricular septal rupture after alcohol septal ablation for obstructive hypertrophic cardiomyopathy?

Bol Guus 2016, In: International Journal of Cardiology.

DDX3, a potential target for cancer treatment

Bol Guus Martinus, Xie Min, Raman Venu 5 nov 2015, In: Molecular Cancer. 14

NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3

Bol Guus 2015, In: Oncotarget.

Targeting DDX3 in cancer: personalized drug development and delivery

Bol G.M. 2 dec 2013, 135 p.

Expression of the RNA helicase DDX3 and the hypoxia response in breast cancer

Bol G.M., Raman V., van der Groep P., Vermeulen J.F., Patel A.H., van der Wall E., van Diest P.J. 2013, In: PLoS ONE [E]. 8